2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 258

Health Services Utilization as Recommended by the American Diabetes Association Among Middle-Aged Patients Disabled with Rheumatoid Arthritis and Diabetes Mellitus
Abstract Number: 1756

Health-related Social Media Use by Parents of Children with Rheumatic Diseases
Abstract Number: 1656

Health-Related Quality of Life in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): Impact of Lung Function on Patient-Reported Outcomes in a Randomized Phase III Trial
Abstract Number: 1470

Health-Related Quality of Life in Primary Sjogren’s Syndrome: Insights from Using PROMIS and Comparison to ESSPRI
Abstract Number: 1123

Healthcare Factors More Predictive of Smoking Cessation in Patients with Rheumatoid Arthritis Than Patient Characteristics
Abstract Number: 2677

Healthcare Resources Utilization in Giant Cell Arteritis – a Population-Based Study
Abstract Number: 1593

Heart Rate Visit-to-Visit Variability in Patients with Systemic Lupus Erythematosus Is Associated with Increased Mortality
Abstract Number: 1994

Helicobacter Pylori Infection Among Korean Patients with Rheumatoid Arthritis and Its Interaction with Shared Epitope
Abstract Number: 803

Hepatitis a Virus Vaccination in Autoinflammatory Diseases Under Canakinumab and Tocilizumab Treatment
Abstract Number: 2101

Hepatitis C Affects More Than Just the Liver: A Retrospective Chart Review on the Prevalence of Connective Tissue Diseases and Autoantibodies in Hepatitis C Virus Infections in an Academic Rheumatology Clinic
Abstract Number: 2406

Hepatobiliary Events in >5000 Patients with Inflammatory Arthritis Treated with Biosimilar or Originator Etanercept in Routine Care, Results from the Danish Nationwide DANBIO Registry
Abstract Number: 1566

HER2 as a Biomarker of Proliferative Lupus Nephritis in Children
Abstract Number: 1104

Heritability and Familial Risk of Systemic Lupus Erythematosus in Sweden: A Population-based Case-control Study
Abstract Number: 1420

Heterogeneity in the Pattern of Use of JAK-inhibitors Between Countries Participating in an International Collaboration of Registers of Rheumatoid Arthritis Patients (the JAK-pot Study)
Abstract Number: 165

Heterogeneity of Strategies and Methods for Assessment of Competences in Rheumatology Training: Results of a Systematic Literature Review to Inform EULAR Points to Consider

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].